Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADJUPANC: Adjuvant Chemoradiotherapy vs Chemotherapy for Pancreatic Cancer
NCT06427447Phase 3Recruiting
- Sponsor
- Changhai Hospital
- Start
- Aug 2024
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Changhai Hospital. Primary endpoint: Disease Progression Free Survival at 3 years. Started Aug 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06427447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427447.